Romiplostim - Biologic Drug Details

Summary for romiplostim

Tradenames:	1
High Confidence Patents:	4
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for romiplostim

Recent Clinical Trials for romiplostim

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Nantes University Hospital	PHASE2
Qilu Pharmaceutical Co., Ltd.	PHASE3
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	NA

See all romiplostim clinical trials

Pharmacology for romiplostim

Mechanism of Action	Thrombopoietin Receptor Agonists
Physiological Effect	Increased Megakaryocyte Maturation Increased Platelet Production
Established Pharmacologic Class	Thrombopoietin Receptor Agonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for romiplostim Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for romiplostim Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	NPLATE	romiplostim	For Injection	125268		2035-03-24	DrugPatentWatch analysis and company disclosures
Amgen Inc.	NPLATE	romiplostim	For Injection	125268		2019-10-22	DrugPatentWatch analysis and company disclosures
Amgen Inc.	NPLATE	romiplostim	For Injection	125268		2023-07-31	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for romiplostim Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Amgen Inc.	NPLATE	romiplostim	For Injection	125268		2036-12-20	Patent claims search
Amgen Inc.	NPLATE	romiplostim	For Injection	125268		2035-11-20	Patent claims search
Amgen Inc.	NPLATE	romiplostim	For Injection	125268		2034-03-14	Patent claims search

International Patents for romiplostim

Country	Patent Number	Estimated Expiration
Spain	2388341
European Patent Office	1783222
Japan	2002536960

Supplementary Protection Certificates for romiplostim

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300398	Netherlands		PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090206
C 2009 009	Romania		PRODUCT NAME: NPLATE-ROMIPLOSTIM; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/497/001, RO EU/1/08/497/002; DATE OF NATIONAL AUTHORISATION: 20090204; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/08/497/001, EMEA EU/1/08/497/002; DATE OF FIRST AUTHORISATION IN EEA: 20090204
25/2009	Austria		PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204

Romiplostim Market Analysis and Financial Projection

Last updated: February 13, 2026

Market Dynamics for Romiplostim

Romiplostim, a thrombopoietin receptor agonist, is primarily used to treat immune thrombocytopenia (ITP). Its market environment is shaped by competitive therapies, regulatory landscapes, and the evolving needs of thrombocytopenia management.

Competitive Landscape

Romiplostim faces competition mainly from:

• Eltrombopag (Promacta, Revolade): Oral thrombopoietin receptor agonist
• Avatrombopag (Doptelet): Approved for chronic ITP and thrombocytopenia associated with chronic liver disease
• Romiplostim's niche remains in refractory ITP, where its intravenous administration is advantageous for certain patient segments

Regulatory Environment

The FDA approved romiplostim in 2008 for chronic ITP. The European Medicines Agency approved it in 2009. Market access for new indications remains limited, with some extended approvals for thrombocytopenia associated with chronic liver disease in specific regions. Regulatory restrictions influence market potential and competitive positioning.

Market Drivers

Key drivers include:

• Growing prevalence of ITP, especially among adult populations
• Increased awareness and improved diagnostics
• Expanding use in hospital settings for refractory cases
• Limited oral options in certain markets, positioning romiplostim as a key injectable therapy

Market Constraints

• High treatment costs limit use in resource-constrained settings
• Need for injections influences patient preference, especially when oral options are available
• Safety concerns, such as rare thrombotic events, affect prescribing patterns

Geographic Variability

North America remains the largest market due to higher disease prevalence and healthcare spending. Europe follows, with expanding markets in Asia-Pacific driven by rising ITP cases and increased healthcare infrastructure.

Financial Trajectory

Revenue and Revenue Drivers

Romiplostim generated approximately $300 million globally in 2022, with North American markets accounting for over 60%. Growth projections suggest a compound annual growth rate (CAGR) of 4-6% over the next five years, driven by:

• Expanded indications, such as thrombocytopenia in cancer patients undergoing chemotherapy
• Greater adoption in countries with increasing healthcare access
• New formulation and delivery method studies

Investment and R&D Spending

Major pharmaceutical companies, including Amgen (original developer), continue investing in R&D:

• Development of biosimilars expected to increase competition
• Research into alternative compounds for thrombocytopenia management

Patent Landscape and Generic Entry

Romiplostim’s patent protection is set to expire around 2026. Biosimilar entrants anticipated from 2025 onward could significantly impact pricing, revenues, and market share.

Cost Dynamics

Treatment costs range from $70,000 to $110,000 annually per patient. The high expense heightens the focus from payers on value-based arrangements and risk-sharing agreements.

Future Revenue Prospects

Long-term growth hinges on:

• Regulatory approvals in emerging markets
• Approval for additional indications (e.g., chemotherapy-induced thrombocytopenia)
• Competition from biosimilars and other therapeutic agents

Key Considerations for Stakeholders

• Market entry strategies must consider patent timelines and biosimilar developments
• Payers increasingly pressure for cost-effective therapies, incentivizing value-based contracts
• Ongoing monitoring of safety profiles influences clinician adoption

Key Takeaways

• Romiplostim's market is driven by its role in refractory ITP management, with competition from oral agents and emerging biosimilars
• Revenues are stable but face pressure from patent expiries and biosimilar entries from 2025 onward
• Cost and administration routes influence adoption; growth relies on expanding indications and geographic penetration
• North America dominates sales; expanding in Asia-Pacific remains a key opportunity
• Regulatory restrictions and safety concerns continue to shape its market dynamics

FAQs

1. When is romiplostim’s patent set to expire?
Patent protection is anticipated to end around 2026, opening the market to biosimilars.

2. How does romiplostim compare with eltrombopag in terms of usage?
Romiplostim is administered via injection, typically in hospitals, while eltrombopag is oral, allowing outpatient use. The choice depends on patient tolerability, disease severity, and clinician preference.

3. What are the main cost considerations for romiplostim?
Annual treatment costs range between $70,000 and $110,000, influencing payer and healthcare provider decisions.

4. Are there new indications for romiplostim?
Research focuses on expanding use in chemotherapy-induced thrombocytopenia and other thrombocytopenic conditions, but regulatory approvals are pending.

5. What is the impact of biosimilars on romiplostim’s market?
Biosimilars entering the market from 2025 will likely reduce prices and potentially decrease revenue share for the originator.

---

Sources:

1. Amgen Annual Report 2022.
2. FDA Approval Documents, 2008.
3. European Medicines Agency Approvals, 2009.
4. Market Intelligence Reports, 2022-2023.
5. Billing and Reimbursement Data, 2022.